Nkarta (NKTX) grants RSUs and 139,000-share stock option to CMO

Rhea-AI Filing Summary

Nkarta, Inc. insider Rose Shawn Marshall, the company’s Chief Medical Officer and Head of Research & Development, reported new equity awards on a Form 4. On January 6, 2026, Marshall received 70,000 shares of Common Stock in the form of Restricted Stock Units, granted at $0 per share. These RSUs vest in four equal annual installments beginning on January 14, 2027, with each RSU representing one share of Nkarta common stock.

On the same date, Marshall was also granted a stock option to buy 139,000 shares of Common Stock at an exercise price of $1.93 per share. This option is scheduled to vest in 48 equal monthly installments, based on continued service after January 14, 2026, and expires on January 5, 2036. Both awards are reported as directly owned following these transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rose Shawn Marshall

(Last) (First) (Middle)

C/O NKARTA, INC.

1150 VETERANS BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nkarta, Inc. [ NKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		70,000(1)	A	$0	70,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.93	01/06/2026		A		139,000		(2)	01/05/2036	Common Stock	139,000	$0	139,000	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

2. This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2026.

Remarks:

Chief Medical Officer, Head of Research & Development

	/s/ Bridgette Housley, as Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rose Shawn Marshall report for NKTX?

Rose Shawn Marshall reported receiving 70,000 Restricted Stock Units of Nkarta common stock and a stock option for 139,000 shares on January 6, 2026, both recorded as directly owned.

How many Nkarta (NKTX) RSUs did the Chief Medical Officer receive?

The Chief Medical Officer, Rose Shawn Marshall, received 70,000 RSUs of Nkarta common stock, granted at $0 per share.

What is the vesting schedule for Rose Shawn Marshall’s RSUs at Nkarta (NKTX)?

The 70,000 RSUs vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Nkarta common stock.

What stock options did Rose Shawn Marshall receive from Nkarta (NKTX)?

Marshall received a stock option to buy 139,000 shares of Nkarta common stock with an exercise price of $1.93 per share, granted on January 6, 2026.

How do the Nkarta (NKTX) stock options granted to Rose Shawn Marshall vest?

The option for 139,000 shares is scheduled to vest and become exercisable in 48 equal monthly installments, based on each month of service to Nkarta following January 14, 2026.

What is the expiration date of Rose Shawn Marshall’s Nkarta (NKTX) stock options?

The stock option for 139,000 shares of Nkarta common stock expires on January 5, 2036, as disclosed in the filing.

Are Rose Shawn Marshall’s Nkarta (NKTX) equity awards held directly or indirectly?

Both the 70,000 RSUs and the 139,000-share stock option are reported as directly owned by Rose Shawn Marshall, with no indirect ownership entity disclosed.